NCT03749460View on ClinicalTrials.gov

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

November 5, 2022

Study Completion Date

November 5, 2023

Conditions
Metastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the LungSalivary Gland CarcinomaStage IV Major Salivary Gland Cancer AJCC v8Stage IVA Major Salivary Gland Cancer AJCC v8Stage IVB Major Salivary Gland Cancer AJCC v8Stage IVC Major Salivary Gland Cancer AJCC v8
Interventions
BIOLOGICAL

Nivolumab

Given IV

BIOLOGICAL

Ipilimumab

Given IV

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER

NCT03749460 - Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers | Biotech Hunter | Biotech Hunter